WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > MetroHealth Station
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
Medical
GT Biopharma | December 23, 2020
GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology organization focused in on innovative treatments dependent on the Company's restrictive NK cell engager (TriKE™) innovation stage is satisfied to report the introduction of extra interval information results for the Company's lead therapeutic competitor, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, i...
Publicist360 | April 09, 2020
Cytogenetics is a branch of biology, which correlates cytology and genetics. The correlation is used to study chromosomes and genes in cells and tissues. The study is conducted in relation to hereditary and variations in genes and number of chromosomes, which are used for the detection of genetic disorders as well as selection of precise therapies for treatment of these genetic disorders. Cytogenetics includes various techniques such as comparative genomic hybridization, fluorescence in situ hyb...
Labiotech.eu | January 28, 2020
A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....
Research, Diagnostics
Businesswire | July 28, 2023
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the “Company”), announces today the availability of an amendment to its 2022 Universal Registration Document, filed by the Company with the Autorité des Marchés Financiers ("AMF") on July 26, 2023, under number D.23-0346-A01, and an admission P...
Cell and Gene Therapy
Whitepaper
Industry Outlook
Cell and Gene Therapy, Industrial Impact
Industrial Impact, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE